1
|
Ma L, Wang S, Zhao H, Yu M, Deng X, Jiang Y, Cao Y, Li P, Niu W. Susceptibility of ApoB and PCSK9 Genetic Polymorphisms to Diabetic Kidney Disease Among Chinese Diabetic Patients. Front Med (Lausanne) 2021; 8:659188. [PMID: 33889589 PMCID: PMC8055819 DOI: 10.3389/fmed.2021.659188] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/27/2021] [Accepted: 03/12/2021] [Indexed: 11/28/2022] Open
Abstract
This study aimed to investigate the susceptibility of 8 polymorphisms in ApoB and PCSK9 genes to diabetic kidney disease (DKD) in Chinese patients with type 2 diabetes mellitus. This is a case-control association study, including 575 DKD cases and 653 controls. Genotypes were determined using ligase detection reaction method, and data are analyzed using STATA software. The genotype distributions of rs1042034 and rs12720838 differed significantly between the two groups (P < 0.001 and P = 0.008, respectively). After adjusting for confounding factors, the mutations of rs1042034 and rs12720838 were associated with the significantly increased risk of DKD. For instance, carriers of rs1042034 T allele (CT and TT genotypes) were 1.07 times more likely to have DKD than carriers of rs1042034 CC genotype [odds ratio (OR) = 1.07, 95% confidence interval (CI): 1.03–1.10, P < 0.001]. Further, haplotype T-A-G-T in ApoB gene was overrepresented in cases (18.10%) compared with controls (12.76%) (PSimulated = 0.045), and haplotype T-A-G-T was associated with a 33% increased risk of DKD (OR = 1.33, 95% CI: 1.04, 1.70). In further haplotype-phenotype analysis, significant association was only noted for hypertension and omnibus haplotypes in ApoB gene (PSimulated = 0.001). Our findings indicate that ApoB gene is a candidate gene for DKD in Chinese patients with type 2 diabetes mellitus.
Collapse
Affiliation(s)
- Liang Ma
- Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
| | - Shaoting Wang
- Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
| | - Hailing Zhao
- Beijing Key Laboratory of Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China
| | - Meijie Yu
- Department of Nephrology, China-Japan Friendship Hospital, Beijing, China
| | - Xiangling Deng
- Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China
| | - Yongwei Jiang
- Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
| | - Yongtong Cao
- Clinical Laboratory, China-Japan Friendship Hospital, Beijing, China
| | - Ping Li
- Beijing Key Laboratory of Immune-Mediated Inflammatory Diseases, Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China
| | - Wenquan Niu
- Institute of Clinical Medical Science, China-Japan Friendship Hospital, Beijing, China
| |
Collapse
|
2
|
Weinrauch LA, D'Elia JA, Weir MR, Bunnapradist S, Finn P, Liu J, Claggett B, Monaco AP. Does diabetes impact therapeutic immunomodulation therapy decisions for kidney transplant recipients? Data from the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial. Int J Nephrol Renovasc Dis 2017; 10:233-242. [PMID: 28860838 PMCID: PMC5571849 DOI: 10.2147/ijnrd.s139901] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/25/2022] Open
Abstract
Although survival has improved for kidney transplant recipients over the past several decades, long-term survival in diabetic cohorts still is significantly less than that of non-diabetic cohorts. We hypothesized that among stable kidney transplant recipients, there might be differences between subgroups with and without diabetes with respect to prevalence of prior cardiovascular events and post-transplant antihypertensive and immunosuppressive therapy. We performed a post hoc analysis of participants in the Folic Acid for Vascular Outcome Reduction in Transplant (FAVORIT) trial, a multicenter international trial of 4110 prevalent kidney transplant recipients enrolled from 2002 to 2007 evaluating the effect of homocysteine-lowering vitamin therapy on cardiovascular outcomes. There were 2447 participants without diabetes, 166 with type 1 diabetes, and 1447 with type 2 diabetes at study entry, which occurred on average 4 years post-transplant. Recipients with diabetes had a greater prevalence of prior cardiovascular events, were more likely to have required multiple medications to control hypertension, and were more likely to have received tacrolimus as opposed to cyclosporine than the non-diabetic transplant recipients (all p<0.001). The effect of differences in treatment of non-diabetic vs diabetic cohorts after stable renal transplantation upon outcomes has not yet been studied and could provide additional information that might lead to improved care.
Collapse
Affiliation(s)
- Larry A Weinrauch
- Cardiovascular Division, Brigham and Women's Hospital, Boston, MA.,Kidney and Hypertension Section,Joslin Diabetes Center, Boston, MA.,Medicine and Surgery, Beth Israel Deaconess Medical Center, Boston MA.,Harvard Medical School, Boston MA
| | - John A D'Elia
- Kidney and Hypertension Section,Joslin Diabetes Center, Boston, MA.,Medicine and Surgery, Beth Israel Deaconess Medical Center, Boston MA.,Harvard Medical School, Boston MA
| | - Matthew R Weir
- University of Maryland School of Medicine, Baltimore, MD
| | - Suphamai Bunnapradist
- Division of Nephrology, Department of Medicine University of California at Los Angeles, Los Angeles, CA, USA
| | - Peter Finn
- Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
| | - Jiankang Liu
- Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
| | - Brian Claggett
- Cardiovascular Division, Brigham and Women's Hospital, Boston, MA
| | - Anthony P Monaco
- Medicine and Surgery, Beth Israel Deaconess Medical Center, Boston MA.,Harvard Medical School, Boston MA
| |
Collapse
|